JP7735285B2 - Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 - Google Patents

Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Info

Publication number
JP7735285B2
JP7735285B2 JP2022549088A JP2022549088A JP7735285B2 JP 7735285 B2 JP7735285 B2 JP 7735285B2 JP 2022549088 A JP2022549088 A JP 2022549088A JP 2022549088 A JP2022549088 A JP 2022549088A JP 7735285 B2 JP7735285 B2 JP 7735285B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022549088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526149A (ja
JP2023526149A5 (https=
JPWO2021163477A5 (https=
Inventor
レヴィン、ノーム
アール． パーカスト、マリア
サード、フランク ジェイ． ロウリー、ザ
エー． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2023526149A publication Critical patent/JP2023526149A/ja
Publication of JP2023526149A5 publication Critical patent/JP2023526149A5/ja
Publication of JPWO2021163477A5 publication Critical patent/JPWO2021163477A5/ja
Application granted granted Critical
Publication of JP7735285B2 publication Critical patent/JP7735285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
JP2022549088A 2020-02-14 2021-02-12 Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 Active JP7735285B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976655P 2020-02-14 2020-02-14
US62/976,655 2020-02-14
US202063060340P 2020-08-03 2020-08-03
US63/060,340 2020-08-03
PCT/US2021/017852 WO2021163477A1 (en) 2020-02-14 2021-02-12 Hla class i-restricted t cell receptors against ras with g12v mutation

Publications (4)

Publication Number Publication Date
JP2023526149A JP2023526149A (ja) 2023-06-21
JP2023526149A5 JP2023526149A5 (https=) 2024-02-26
JPWO2021163477A5 JPWO2021163477A5 (https=) 2024-02-26
JP7735285B2 true JP7735285B2 (ja) 2025-09-08

Family

ID=74860482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549088A Active JP7735285B2 (ja) 2020-02-14 2021-02-12 Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Country Status (12)

Country Link
US (1) US20230082787A1 (https=)
EP (1) EP4103598A1 (https=)
JP (1) JP7735285B2 (https=)
KR (1) KR20220143875A (https=)
CN (1) CN115315441A (https=)
AU (1) AU2021220957A1 (https=)
BR (1) BR112022015897A2 (https=)
CA (1) CA3167382A1 (https=)
GB (1) GB2610311B (https=)
MX (1) MX2022009825A (https=)
TW (1) TWI902755B (https=)
WO (1) WO2021163477A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2023232785A1 (en) * 2022-05-30 2023-12-07 Hs Diagnomics Gmbh Common tumor-specific t cell receptors
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
JP2017536825A (ja) 2014-11-26 2017-12-14 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
WO2019060349A1 (en) 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017536825A (ja) 2014-11-26 2017-12-14 アメリカ合衆国 抗突然変異ｋｒａｓ ｔ細胞受容体
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
WO2019060349A1 (en) 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunol. Res.，2015年，Vol.4，pp.204-214

Also Published As

Publication number Publication date
TW202140535A (zh) 2021-11-01
JP2023526149A (ja) 2023-06-21
GB2610311A (en) 2023-03-01
KR20220143875A (ko) 2022-10-25
CN115315441A (zh) 2022-11-08
EP4103598A1 (en) 2022-12-21
US20230082787A1 (en) 2023-03-16
MX2022009825A (es) 2022-10-13
TWI902755B (zh) 2025-11-01
GB202211757D0 (en) 2022-09-28
WO2021163477A8 (en) 2022-09-29
GB2610311B (en) 2025-07-09
CA3167382A1 (en) 2021-08-19
AU2021220957A1 (en) 2022-09-01
BR112022015897A2 (pt) 2022-10-18
WO2021163477A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7620676B2 (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7735285B2 (ja) Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7832111B2 (ja) Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
US20260008832A1 (en) Hla class ii-restricted t cell receptors against ras with g12r mutation
CA3116749A1 (en) Hla-a3-restricted t cell receptors against mutated ras
JP2023534241A (ja) Ｇ１２ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250827

R150 Certificate of patent or registration of utility model

Ref document number: 7735285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150